2. Academic Validation
  3. Direct cell-to-cell transfer in stressed tumor microenvironment aggravates tumorigenic or metastatic potential in pancreatic cancer

Direct cell-to-cell transfer in stressed tumor microenvironment aggravates tumorigenic or metastatic potential in pancreatic cancer

  • NPJ Genom Med. 2022 Oct 27;7(1):63. doi: 10.1038/s41525-022-00333-w.
Giyong Jang 1 2 3,  Jaeik Oh 4 5,  Eunsung Jun 6 7 8,  Jieun Lee 1 2 9,  Jee Young Kwon 1 2 10,  Jaesang Kim 1 2,  Sang-Hyuk Lee 1 2 11,  Song Cheol Kim 6 7 8,  Sung-Yup Cho 12 13 14 15,  Charles Lee 16 17 18
Affiliations

Affiliations

  • 1 Department of Life Science, Ewha Womans University, Seoul, 03760, Republic of Korea.
  • 2 Ewha-JAX Cancer Immunotherapy Research Center, Ewha Womans University, Seoul, 03760, Republic of Korea.
  • 3 Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
  • 4 Department of Translational Medicine, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea.
  • 5 Department of Internal Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
  • 6 Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
  • 7 Asan Medical Institute of Convergence Science and Technology (AMIST), Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
  • 8 Department of Convergence Medicine, Asan Institute for Life Sciences, University of Ulsan College of Medicine and Asan Medical Center, Seoul, 05505, Republic of Korea.
  • 9 Department of Surgery, Seoul National University Bundang Hospital, Gyeonggi-do, 13620, Republic of Korea.
  • 10 The Jackson Laboratory for Genomic Medicine, Farmington, CT, 06032, USA.
  • 11 Department of Bio-Information Science, Ewha Womans University, Seoul, 03760, Republic of Korea.
  • 12 Medical Research Center, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea. [email protected].
  • 13 Department of Translational Medicine, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea. [email protected].
  • 14 Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea. [email protected].
  • 15 Cancer Research Institute, Seoul National University, Seoul, 03080, Republic of Korea. [email protected].
  • 16 Department of Life Science, Ewha Womans University, Seoul, 03760, Republic of Korea. [email protected].
  • 17 Ewha-JAX Cancer Immunotherapy Research Center, Ewha Womans University, Seoul, 03760, Republic of Korea. [email protected].
  • 18 The Jackson Laboratory for Genomic Medicine, Farmington, CT, 06032, USA. [email protected].
PMID: 36302783 DOI: 10.1038/s41525-022-00333-w
Abstract

Pancreatic Cancer exhibits a characteristic tumor microenvironment (TME) due to enhanced fibrosis and hypoxia and is particularly resistant to conventional chemotherapy. However, the molecular mechanisms underlying TME-associated treatment resistance in pancreatic Cancer are not fully understood. Here, we developed an in vitro TME mimic system comprising pancreatic Cancer cells, fibroblasts and immune cells, and a stress condition, including hypoxia and gemcitabine. Cells with high viability under stress showed evidence of increased direct cell-to-cell transfer of biomolecules. The resulting derivative cells (CD44high/SLC16A1high) were similar to Cancer stem cell-like-cells (CSCs) with enhanced anchorage-independent growth or invasiveness and acquired metabolic reprogramming. Furthermore, CD24 was a determinant for transition between the tumorsphere formation or invasive properties. Pancreatic Cancer patients with CD44low/SLC16A1low expression exhibited better prognoses compared to other groups. Our results suggest that crosstalk via direct cell-to-cell transfer of cellular components foster chemotherapy-induced tumor evolution and that targeting of CD44 and MCT1(encoded by SLC16A1) may be useful strategy to prevent recurrence of gemcitabine-exposed pancreatic cancers.

Figures
Products